Importantly, age was not significantly related to a worse ECOG (p = 0.11; Chi-square test), but it was related to the initiation of radiochemotherapy (p = 0.001; Chi-square test) and the prescription of an adjuvant chemotherapy (p = 0.005; Chi-square test). Furthermore, we asked whether the subgroup patients with an ECOG of 1 or 2 would benefit from RChT or not. The median OS of ECOG 1 patients was 7 and 16.3 months with RT and RChT, respectively (Fig. 4a). The difference was not significant (p = 0.174), however, this is most likely due to the low patient number of this subgroup. In comparison to this, the median OS of patients with an ECOG of 2 was 6.2 and 7.2 with RT and RChT (Fig. 4b). Also this difference was not significant (p = 0.774).Fig. 4Kaplan Meier estimares for patients undergoing RT and RChT. In patients with ECOG 1 (a), median OS 7 vs. 16.3 months. In patients with ECOG 2 (b), median OS was 6.2 vs. 7.2